Another hypothesis is that a patient may have EGPA intrinsically, but prior IL-5/IL-5R antibody therapy has suppressed the onset of symptoms, and the switch from these drugs to dupilumab may cause EGPA. This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.